Abstract 179P
Background
HCC is the fourth most common malignancy in China, and ranks second by mortality rate. Most patients have already reached advanced stage when diagnosed. TACE in combination with first-lined systematic therapy has been explored as an effective treatment for unresectable HCC. However, it has not been reported the safety and efficacy of Regorafenib combined with TACE, as a second-lined therapy. In this multicenter retrospective study, we preliminarily investigated the safety and efficacy of a combination with Regorafenib and TACE therapy in patients with unresectable HCC.
Methods
We reviewed the medical data of 38 patients with progression after prior treatment of Sorafenib and/or Lenvatinib from Jan 2019 to Apr 2020 at 4 tertiary centers in China. Patients were treated with TACE initially after enrollment. 5-7 days after the first TACE, patients started taking Regorafenib PO for 3 weeks on/1 week off. All patients were required to be followed up regularly and TACE was repeated as needed. The overall survival (OS), time to progression (TTP), progression-free survival (PFS), drugs safety, adverse events (AEs) were observed. OS was calculated from date of first TACE to death. TTP was calculated from date of first TACE to progression. Adverse events were evaluated by Clavien classification. Drugs safety was investigated according to CTCAE v4.03.
Results
Baseline patient characteristics are presented in the table Table: 179P
Baseline patient characteristics
Baseline characteristic | Total (n=38) |
Age (years) | 59.4±9.19 |
Sex, n (%) | |
Male | 32 (84.2%) |
ECOG, n (%) | |
0 | 21 (55.3%) |
1 | 13 (34.2%) |
2 | 4 (10.5%) |
BCLC, n (%) | |
B | 18 (47.4%) |
C | 20 (52.6%) |
Hepatitis, n (%) | |
HBV | 32 (84.2%) |
HCV | 2 (5.3%) |
No | 4 (10.5%) |
Maximum tumor size (cm) | 3.75 (2.5, 7.5) |
Tumor number, n (%) | |
1 | 4 (10.5%) |
≥2 | 34 (89.5%) |
AFP (μg/L) | 50.85 (6.64, 1210) |
Extrahepatic metastasis, n (%) | 13 (34.2%) |
Portal vein invasion, n (%) | 12(31.6%) |
Prior Local Therapy, n (%) | |
Surgery | 13 (34.2%) |
Ablation | 20 (52.6%) |
TACE | 36 (94.7%) |
Radiotherapy | 6 (15.8%) |
Follow-up, months(range) | 5.6 (1.7,17.0) |
Prior Systemic Therapy, n(%) Sorafenib Lenvatinib Lenvatinib Sequential to Sorafenib | 33 (86.8%) 1(2.6%) 4(10.5%) |
Conclusions
Regardless of the retrospective nature, the present study as the first up-to-date real-world evidence indicates that Regorafenib combined with TACE was clinically effective and tolerable in subsequent to prior systemic therapy for unresectable HCC. Additional prospective large-scale studies are required to further verify our conclusion.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
372P - Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study
Presenter: Ross A. Soo
Session: e-Poster Display Session
373P - Chromatin accessibility reveals potential prognostic value of the peak set associated with smoking history in patients with lung adenocarcinoma
Presenter: Jianlian Deng
Session: e-Poster Display Session
384P - BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Presenter: Stefanie Schalm
Session: e-Poster Display Session
385P - Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
Presenter: Fabrice Barlesi
Session: e-Poster Display Session
386P - A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: LI Zhou
Session: e-Poster Display Session
387P - Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
Presenter: Tomonori Hirashima
Session: e-Poster Display Session
388P - Biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients
Presenter: Zhen Zhou
Session: e-Poster Display Session
389P - Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
Presenter: Yi-Long Wu
Session: e-Poster Display Session
391P - Economic impact of next-generation sequencing (NGS) versus single-gene testing modalities to detect genomic alterations (GAs) in metastatic non-small cell lung cancer (mNSCLC) in Asia
Presenter: Herbert Loong
Session: e-Poster Display Session
392P - Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-positive non-small cell lung cancer patients with brain metastases in China
Presenter: Zhixin Qiu
Session: e-Poster Display Session